Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats

Diabetes

Volumn 50, Issue 5, 2001, Pages 1004-1011

  Lynn, Francis C ^a   Pamir, Nathalie ^a   Ng, Eddy H C ^a   McIntosh, Christopher H S ^a   Kieffer, Timothy J ^b   Pederson, Raymond A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; INSULIN; PEPTIDE HORMONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RELEASE; NONHUMAN; PANCREAS PERFUSION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT;

EID: 0035041250     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.5.1004     Document Type: Article

References (43)

1. Peptide hormone regulation of islet cells
2. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor
3. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: Ligand binding and intracellular signaling properties
4. Cloning and functional expression of the human islet GLP-1 receptor: Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor
5. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1
6. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells
7. Characterization of the carboxyl-terminal domain of the rat glucose-dependent insulinotropic polypeptide (GIP) receptor: A role for serines 426 and 427 in regulating the rate of internalization
8. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor
9. Effect of GIP and GLP-1 antagonists on insulin release in the rat
10. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
11. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat
12. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene
13. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice
14. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
15. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion
16. The insulinotropic action of gastric inhibitory polypeptide in the perfused rat pancreas
17. Drugs on the horizon for treatment of type 2 diabetes
18. Physiology and pathophysiology of GIP
19. Glucagon-like peptide 1 (GLP-1): A potent gut hormone with a possible therapeutic perspective
20. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential
21. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
22. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
23. The pathogenesis of NIDDM involves a defective expression of the GIP receptor
24. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus
25. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients
26. Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance
27. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM): Evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins
28. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats
29. Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (BTC-3) cells to glucose dependent insulinotropic polypeptide
30. Identification of two missense mutations in the GIP receptor gene: A functional study and association analysis with NIDDM: No evidence of association with Japanese NIDDM subjects
31. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: The impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells
32. Effect of jejunoileal bypass in the rat on the enteroinsular axis
33. Pancreatic islet isolation in rats with ductal collagenase distention, stationary digestion and dextran separation
34. Quantitative RT-PCR: Pitfalls and potential
35. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: Demonstration by a receptor antagonist
36. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
37. Dipeptidyl-peptidase IV (CD26): Role in the inactivation of regulatory peptides
38. The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors
39. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
40. Neuroendocrine peptides of the gastrointestinal tract of an animal model of human type 2 diabetes mellitus
41. Improved glucose tolerance in Zucker fatty rats in oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolide
42. Regulation of glucagon receptor mRNA in cultured primary rat hepatocytes by glucose and cAMP
43. PKA-mediated phosphorylation of the human k-ATP channel: Separate roles of Kir6.2 and SUR1 subunit phosphorylation